12 jul: Aktier/åbning: Hele C20 i rødt
12 jul: G4S lover stor indsats for at sikre OL-vagter
12-07-2012 09:37:00

Actelion Launches First Job Cuts

Relateret indhold

By John Revill

ZURICH--Actelion Ltd. (ATLN.VX) will cut its workforce by up to 5% as part of its new cost-cutting program, as Europe's biggest biotechnology company by sales wrestles with the strong Swiss franc and the tough European market.

The cuts will be the first at Actelion since it was founded in 1997.

The company, based in Allschwil, Switzerland, Thursday said it could reduce up to 135 positions from its 2,500-strong workforce by the end of 2012, but didn't say how much it hopes to save from the cuts.

"In order to take full advantage of the growth opportunities ahead of us, we must take decisive action now," said Chief Executive Jean-Paul Clozel.

Around 70 jobs, mostly in R&D and general administration, are likely go at the Allschwil site in Switzerland, where 1,100 employees are currently based. Another 45 currently vacant positions won't be filled, Actelion said.

Pharmaceutical companies have recently been forced to act on steep drug price cuts in Europe and the U.S. and declining revenues as patents on key drugs expire.

Last month, Swiss pharmaceutical company Roche Holding AG (ROG.VX) said it would close a research-and-development site in Nutley, N.J., while Novartis AG (NVS) said in January it needs to save between $1.5 billion and $2.5 billion this year to stay on track.

Actelion, founded by two former Roche scientists, has been dealt a string of product setbacks, and is now banking on a new lung and heart drug called macitentan to become its new blockbuster product.

The company announced that it would be embarking on a cost-saving program in May. At the time, it said earnings wouldn't grow again until 2014 as new medicines and cost cuts would take time to offset falling sales of key pulmonary hypertension drug Tracleer.

Actelion has previously forecast flat core earnings for 2012 as it prepares for declines in sales of Tracleer, which accounts for around 90% of company sales but goes off patent in 2015.

In the first three months of 2012, the company reported a 16% decline in core earnings in Swiss francs--almost double the 9% fall in local currencies--as the currency traded at high levels against the dollar and the euro.

Actelion also Thursday said it is refocusing its R&D efforts toward rare diseases and specialty indications to generate more specialty franchises.

At 0704 GMT, Actelion shares were down CHF0.31, or 0.8%, at CHF40.56.

Write to John Revill at john.revill@dowjones.com

(END) Dow Jones Newswires

July 12, 2012 03:37 ET (07:37 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Vestas deler sit asiatiske salg op i to - NY

22-02-2017 11:15:07
Vestas forsøger at skabe et stærkere ståsted i Asien og deler sit hidtidige salgskontor i regionen op i to nye: ét til Kina og Mongoliet, og ét til resten af As..

Alternative investeringer hitter blandt de store

07-02-2017 10:29:17
​Sponsoreret indhold:Private investorer kan ligesom de professionelle få solide afkast og risikospredning med en investering i vindenergi. Ny guide viser dig, h..

DFDS: Stærk resultatfremgang, øget udbytte og nyt aktietilbagekøb

07-02-2017 08:41:33
Rederiet DFDS har haft betydelig resultatfremgang i 2016 og forkæler aktionærerne ved at øge udbyttet med en tredjedel og starte aktietilbagekøb for op til 800 ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Tirsdagens aktier: Vestas, Genmab og Lundbeck trak C20 i rekord
2
Genmab-analytiker om Darzalex: Salget starter rigtig flot i 2017
3
Genmab-analytiker: Alle øjne er rettet mod Darzalex-salget i 2017
4
Aktier/tendens: Genmab i fokus på salgstal i ventet positivt marked
5
Pandora åbner for handel med sine aktier i USA

Relaterede aktiekurser

Novartis N 77,30 -0,1% Fald i aktiekurs
Roche GS 245,00 -0,6% Fald i aktiekurs
Actelion N 271,30 0,1% Stigning i aktiekurs
Roche I 248,30 -0,5% Fald i aktiekurs
Novartis AG 77,04 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. februar 2017 13:54:42
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170217.2 - EUROWEB3 - 2017-02-22 13:54:42 - 2017-02-22 13:54:42 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x